1. rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)
- Author
-
Conall H. Watson, Pierre-Stéphane Gsell, Yper Hall, Anton Camacho, Ximena Riveros, Godwin Enwere, Andrea Vicari, Séverine Danmadji Nadlaou, Alhassane Toure, Ismaila M. Sani, Abdourahamane Diallo, Cece Kolie, Sophie Duraffour, Kékoura Ifono, Andre Maomou, Kassie Dore, Honora A. Djidonou, Aminata Bagayoko, Philos P. Damey, Mabetty Nancy Camara, Fatoumata Battouly Diallo, Fofana Thierno Oumar, Kalidou Toure, Mohamed Lamine Diaby, Lansana Sylla, Doussou Conde, Ibrahima Lansana Kaba, Tom Tipton, Rosalind M. Eggo, Michael Marks, Chrissy H. Roberts, Thomas Strecker, Stephan Günther, Sakoba Keita, W. John Edmunds, Miles W. Carroll, and Ana Maria Henao-Restrepo
- Subjects
Ebola virus disease ,Ebola ,Vaccine ,RVSV-ZEBOV ,Safety ,Immunogenicity ,Medicine - Abstract
Abstract Background Zaire Ebolavirus disease (EVD) outbreaks can be controlled using rVSV-ZEBOV vaccination and other public health measures. People in high-risk areas may have pre-existing antibodies from asymptomatic Ebolavirus exposure that might affect response to rVSV-ZEBOV. Therefore, we assessed the impact pre-existing immunity had on post-vaccination IgG titre, virus neutralisation, and reactogenicity following vaccination. Methods In this prospective cohort study, 2115 consenting close contacts (“proches”) of EVD survivors were recruited. Proches were vaccinated with rVSV-ZEBOV and followed up for 28 days for safety and immunogenicity. Anti-GP IgG titre at baseline and day 28 was assessed by ELISA. Samples from a representative subset were evaluated using live virus neutralisation. Results Ten percent were seropositive at baseline. At day 28, IgG in baseline seronegative (GMT 0.106 IU/ml, 95% CI: 0.100 to 0.113) and seropositive (GMT 0.237 IU/ml, 0.210 to 0.267) participants significantly increased from baseline (both p
- Published
- 2024
- Full Text
- View/download PDF